Last reviewed 2026-05-15 · How we verify

Esyntin ((2-benzhydryloxyethyl)diethyl-methylammonium iodide)

Esyntin (generic name: (2-benzhydryloxyethyl)diethyl-methylammonium iodide) is a (2-benzhydryloxyethyl)diethyl-methylammonium iodide drug. It is currently in unknown development.

Esyntin works by binding to specific biological molecules to produce a therapeutic effect.

Esyntin, also known as (2-benzhydryloxyethyl)diethyl-methylammonium iodide, is a small molecule drug of unknown target and class. Its commercial status and approved indications are currently unknown. As a small molecule, Esyntin is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand Esyntin's properties and potential uses.

At a glance

Mechanism of action

Think of Esyntin like a key that fits into a lock. The key (Esyntin) binds to a specific lock (biological molecule) to turn it on or off, which can help to treat a particular disease or condition. This binding process is what allows Esyntin to produce its therapeutic effect.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Esyntin CI brief — competitive landscape report
• Esyntin updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Esyntin

Related

• Drug class: All (2-benzhydryloxyethyl)diethyl-methylammonium iodide drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing